Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

This study reviews drug-induced hair changes, noting that hair loss often reverses after stopping the drug, but permanent alopecia cases post-chemotherapy are rising.

This study observed that in Korean HIV patients, tinea infection, folliculitis, and seborrheic dermatitis were the most common skin diseases, with HAART medications generally reducing folliculitis incidence. Skin disease prevalence differed by immune status, affecting treatment needs.

This article reviews drug-induced pigmentation and reports no new clinical findings, highlighting difficulty in confirming drug associations due to factors like delayed onset and polypharmacy.